Takeda Raises Full-Year, Entyvio Forecasts On Solid H1
On Look Out For R&D Assets
Executive Summary
While it is benefiting handsomely from the near 50-year low of the yen, Takeda said strong underlying growth for its mainstays in the fiscal first half was one factor behind its raised full-year forecast, and the Japanese major also sees a brighter long-term outlook for global blockbuster Entyvio.
You may also be interested in...
IBD Market Snapshot: Changes Ahead, But Current Biologics Are Formidable Competitors
The ulcerative colitis and Crohn’s disease landscapes may shift soon but new drugs will compete with entrenched blockbusters, including Humira, Stelara and Entyvio, with biosimilars on the way.
Takeda Takes Collaborative, Educational Approach In Thai Dengue Initiative
As it looks to roll out its new dengue vaccine globally, Takeda will work with Kao’s Thai subsidiary on education and prevention activities in Bangkok, later expanding these to wider areas of Thailand, in the first such local collaboration by the private sector.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.